# Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU

> **NCT03990467** · NA · UNKNOWN · sponsor: **Hospices Civils de Lyon** · enrollment: 60 (estimated)

## Conditions studied

- Septic Shock
- Sepsis
- Sepsis Syndrome

## Interventions

- **BIOLOGICAL:** Plasma dosage of amikacin, piperacillin and tazobactam

## Key facts

- **NCT ID:** NCT03990467
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-28
- **Primary completion:** 2023-01-28
- **Final completion:** 2023-01-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03990467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03990467, "Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03990467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*